超越 VEGF：抑制成纤维细胞生长因子途径和抗血管生成。
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.
机构信息
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
出版信息
Clin Cancer Res. 2011 Oct 1;17(19):6130-9. doi: 10.1158/1078-0432.CCR-11-0659. Epub 2011 Sep 27.
Abstract
Fibroblast growth factor (FGF) signaling regulates cell proliferation, differentiation, survival, angiogenesis, and wound healing. Compelling evidence for deregulated FGF signaling in tumorigenesis continues to emerge, and a growing body of research suggests that FGF may also play an integral role in the resistance to anti-VEGF therapy. Although agents targeting FGF signaling are early in development, the potential to target both the VEGF and FGF pathways may translate into improvements in the clinical care of cancer patients.
摘要
成纤维细胞生长因子 (FGF) 信号转导调节细胞增殖、分化、存活、血管生成和伤口愈合。越来越多的证据表明，FGF 信号转导失调在肿瘤发生中起着重要作用，并且越来越多的研究表明，FGF 可能在抗血管内皮生长因子 (VEGF) 治疗的耐药性中发挥重要作用。尽管针对 FGF 信号的药物仍处于早期开发阶段，但靶向 VEGF 和 FGF 通路的潜力可能会改善癌症患者的临床治疗效果。
相似文献
1
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.超越 VEGF：抑制成纤维细胞生长因子途径和抗血管生成。
Clin Cancer Res. 2011 Oct 1;17(19):6130-9. doi: 10.1158/1078-0432.CCR-11-0659. Epub 2011 Sep 27.
2
Dll4-Notch signaling in regulation of tumor angiogenesis.Dll4-Notch 信号通路在肿瘤血管生成调控中的作用。
J Cancer Res Clin Oncol. 2014 Apr;140(4):525-36. doi: 10.1007/s00432-013-1534-x. Epub 2013 Oct 10.
3
Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors.蛋白酪氨酸磷酸酶κ在协调促血管生成因子诱导的血管生成中的双重作用。
Int J Oncol. 2017 Apr;50(4):1127-1135. doi: 10.3892/ijo.2017.3884. Epub 2017 Feb 20.
4
Quinolinone Derivatives Suppress Angiogenesis in Human Umbilical Vein Endothelial Cells by Blocking the VEGF-Induced VEGFR2 Signaling Pathway.喹啉酮衍生物通过阻断血管内皮生长因子（VEGF）诱导的血管内皮生长因子受体2（VEGFR2）信号通路抑制人脐静脉内皮细胞的血管生成。
Arch Pharm (Weinheim). 2025 Jul;358(7):e70040. doi: 10.1002/ardp.70040.
5
Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.抗血管内皮生长因子生物类似药治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2024 Jun 3;6(6):CD015804. doi: 10.1002/14651858.CD015804.pub2.
6
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis.抗血管内皮生长因子药物与激光光凝术治疗糖尿病视网膜病变的比较：系统评价与经济分析
Health Technol Assess. 2025 May 7:1-16. doi: 10.3310/KRWP1264.
7
Growth factors for angiogenesis in peripheral arterial disease.外周动脉疾病中血管生成的生长因子。
Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD011741. doi: 10.1002/14651858.CD011741.pub2.
8
Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis.抗血管内皮生长因子药物与激光光凝术治疗增殖性糖尿病视网膜病变的比较：一项系统评价和个体参与者数据荟萃分析
Health Technol Assess. 2025 Apr 2:1-75. doi: 10.3310/MJYP6578.
9
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.抗血管内皮生长因子治疗视网膜分支静脉阻塞继发的黄斑水肿。
Cochrane Database Syst Rev. 2013 Jan 31(1):CD009510. doi: 10.1002/14651858.CD009510.pub2.
10
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.癌症治疗中针对血管生成：超越血管内皮生长因子
Oncologist. 2015 Jun;20(6):660-73. doi: 10.1634/theoncologist.2014-0465. Epub 2015 May 22.
引用本文的文献
1
Immune Evasion in Head and Neck Squamous Cell Carcinoma: Roles of Cancer-Associated Fibroblasts, Immune Checkpoints, and Mutations in the Tumor Microenvironment.头颈部鳞状细胞癌中的免疫逃逸：肿瘤相关成纤维细胞、免疫检查点及肿瘤微环境中突变的作用
Cancers (Basel). 2025 Aug 7;17(15):2590. doi: 10.3390/cancers17152590.
2
Fibroblast growth factor receptor expression in hemangioblastomas: A novel therapeutic target.成血管细胞瘤中纤维母细胞生长因子受体的表达：一个新的治疗靶点。
PLoS One. 2025 May 20;20(5):e0323979. doi: 10.1371/journal.pone.0323979. eCollection 2025.
3
Perioperative Treatment in Gastric Cancer: A Fast-Changing Field.胃癌的围手术期治疗：一个快速变化的领域。
Cancers (Basel). 2024 Dec 1;16(23):4036. doi: 10.3390/cancers16234036.
4
Progress on angiogenic and antiangiogenic agents in the tumor microenvironment.肿瘤微环境中血管生成剂与抗血管生成剂的研究进展
Front Oncol. 2024 Nov 19;14:1491099. doi: 10.3389/fonc.2024.1491099. eCollection 2024.
5
Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives.接受全身治疗的肝细胞癌患者门静脉高压症的管理：当前证据与未来展望
Cancers (Basel). 2024 Mar 31;16(7):1388. doi: 10.3390/cancers16071388.
6
Dysregulated wound healing in the pathogenesis of urogynecologic mesh complications.泌尿妇科补片并发症发病机制中的失调性伤口愈合。
Sci Rep. 2023 Dec 5;13(1):21437. doi: 10.1038/s41598-023-48388-8.
7
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma.乐伐替尼通过抑制晚期肝细胞癌肿瘤微环境中的免疫抑制浸润来激活抗肿瘤免疫。
Commun Med (Lond). 2023 Oct 25;3(1):152. doi: 10.1038/s43856-023-00390-x.
8
Novel scaffold platforms for simultaneous induction osteogenesis and angiogenesis in bone tissue engineering: a cutting-edge approach.新型支架平台在骨组织工程中同时诱导成骨和血管生成：一种前沿方法。
J Nanobiotechnology. 2023 Sep 28;21(1):351. doi: 10.1186/s12951-023-02115-7.
9
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.富替替尼，一种不可逆的 FGFR1-4 抑制剂，用于治疗 FGFR 异常肿瘤。
Oncologist. 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149.
10
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.血管生成与肝细胞癌：从分子机制到系统治疗。
Medicina (Kaunas). 2023 Jun 9;59(6):1115. doi: 10.3390/medicina59061115.
本文引用的文献
1
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.Brivanib，一种双重 FGF/VEGF 抑制剂，在一线和二线治疗对 VEGF 抑制产生适应性/逃避性耐药的小鼠胰腺神经内分泌肿瘤中均具有活性。
Clin Cancer Res. 2011 Aug 15;17(16):5299-310. doi: 10.1158/1078-0432.CCR-10-2847. Epub 2011 May 27.
2
Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.E7080 治疗晚期实体瘤的 I 期剂量递增研究及生物标志物分析。
Clin Cancer Res. 2011 Apr 15;17(8):2528-37. doi: 10.1158/1078-0432.CCR-10-2638. Epub 2011 Mar 3.
3
Targeting mutant fibroblast growth factor receptors in cancer.针对癌症中的突变型成纤维细胞生长因子受体。
Trends Mol Med. 2011 May;17(5):283-92. doi: 10.1016/j.molmed.2011.01.012. Epub 2011 Mar 1.
4
Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.同时针对多个途径的血管生成：BIBF 1120，一种新型的三重血管激酶抑制剂的研究。
Invest New Drugs. 2012 Jun;30(3):1261-9. doi: 10.1007/s10637-011-9644-2. Epub 2011 Feb 25.
5
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.E-3810 是一种有效的 VEGFR 和 FGFR 双重抑制剂，在多种临床前模型中发挥抗肿瘤活性。
Cancer Res. 2011 Feb 15;71(4):1396-405. doi: 10.1158/0008-5472.CAN-10-2700. Epub 2011 Jan 6.
6
Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.在实体瘤治疗中，将贝伐单抗添加到化疗方案中：结果相似但结论不同。
J Clin Oncol. 2011 Jan 20;29(3):254-6. doi: 10.1200/JCO.2010.32.0275. Epub 2010 Dec 13.
7
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.一项 I 期研究旨在确定双重 VEGFR 和 FGFR 抑制剂布立尼布在晚期或转移性实体瘤患者中的安全性、药代动力学和药效学。
Ann Oncol. 2011 Jun;22(6):1413-1419. doi: 10.1093/annonc/mdq599. Epub 2010 Dec 3.
8
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.布立尼布，一种新型的双重 VEGFR2/碱性成纤维细胞生长因子受体（bFGF-R）抑制剂。
Anticancer Res. 2010 Nov;30(11):4477-83.
9
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.BIBF 1120（一种口服三酪氨酸激酶抑制剂）治疗晚期实体瘤患者的 I 期安全性、药代动力学和生物标志物研究。
Mol Cancer Ther. 2010 Oct;9(10):2825-33. doi: 10.1158/1535-7163.MCT-10-0379. Epub 2010 Aug 5.
10
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.在晚期实体瘤患者中，每日两次口服 TSU-68（一种新型多受体酪氨酸激酶抑制剂），两次服药之间不进食，进行 I 期和药代动力学研究。
Cancer Chemother Pharmacol. 2011 May;67(5):1101-9. doi: 10.1007/s00280-010-1404-z. Epub 2010 Jul 30.
Zotero 插件